Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists

Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and... Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Anatomic Pathology Wolters Kluwer Health

Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists

Loading next page...
 
/lp/wolters-kluwer-health/immune-checkpoint-inhibitor-therapy-principles-and-relevance-of-M1tmk3X35O

References (47)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1072-4109
eISSN
1533-4031
DOI
10.1097/pap.0000000000000373
Publisher site
See Article on Publisher Site

Abstract

Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.

Journal

Advances in Anatomic PathologyWolters Kluwer Health

Published: May 3, 2023

There are no references for this article.